Adicet Bio Q3 net loss narrows 30% to $18.88 million
ACET•Adicet Bio's third-quarter 2026 net loss narrowed 30% year over year to $18.88 million. It had $100.95 million in cash, cash equivalents and short-term investments at September 30, with funding expected to last into the second half of 2027.
1. Costs and cash
Research and development expenses fell 32% year over year to $15.63 million, while general and administrative expenses dropped 18% to $4.17 million. Cash, cash equivalents and short-term investments totaled $100.95 million at September 30, and the company expects funding to last into the second half of 2027.
2. Clinical program updates
Startup activities are underway for a pivotal prula-cel study in lupus nephritis, with a regulatory update and additional 12-month data expected in the first quarter of 2027. Patient enrollment for ADI-212 in metastatic castration-resistant prostate cancer is anticipated in the first quarter of 2027 following FDA clearance of its investigational new drug application.




